Table 3. TLR2 SNPs and FEV1 level at baseline and FEV1 decline.
| SNP | FEV1 level (ml) | p | FEV1 decline (ml/yr) | p | |
| B (95%CI) | E (95%CI) | ||||
| rs1898830 | a | −95.5 (−222.8–31.8) | 0.140 | −2.4 (−4.4–−0.4) | 0.021 |
| b | −267.9 (−522.8–−13.2) | 0.039 | 5.2 (1.4–9.0) | 0.008 | |
| rs3804099 | a | 140.8 (−8.3–289.9) | 0.064 | 1.5 (−0.9–3.8) | 0.219 |
| b | 118.6 (−66.9–304.1) | 0.208 | 3.1 (0.2–5.9) | 0.036 | |
| rs3804100 | a | 116.3 (−57.9–290.5) | 0.188 | 2.5 (−0.2–5.2) | 0.073 |
| rs1816702 | a | 45.8 (−102.7–194.2) | 0.542 | 0.1 (−2.3–2.4) | 0.977 |
| b | 169.9 (−164.5–504.4) | 0.316 | −8.2 (−12.9–−3.4) | 0.001 | |
| rs11938228 | a | −73.0 (−202.4–56.5) | 0.266 | −2.2 (−4.2–−0.1) | 0.042 |
| b | −240.2 (−450.3–−30.1) | 0.025 | 3.1 (−0.2–6.3) | 0.065 | |
| rs7656411 | a | 185.6 (55.1–316.2) | 0.006 | 1.9 (−0.2–4.0) | 0.080 |
| b | −37.6 (−300.8–225.6) | 0.778 | 8.6 (4.7–12.4) | 1.3×10−5 | |
| rs5743704 | a | 114.4 (−123.0–351.8) | 0.341 | −2.8 (−6.5–0.9) | 0.130 |
| rs5743708 | a | −72.1 (−268.8–124.7) | 0.469 | −0.1 (−3.1–2.8) | 0.931 |
| rs4696480 | a | 170.2 (22.6–317.8) | 0.024 | −1.7 (−4.1–0.6) | 0.143 |
| b | 108.2 (−62.1–278.5) | 0.210 | 1.1 (−1.6–3.8) | 0.413 |
FEV1 level adjusted for age, gender, height, pack-year, current smoking; FEV1 decline adjusted for FEV1 baseline, age, gender, height, current smoking, treatment, the period when there is a change in treatment and its interaction with treatment and their interaction with time; a = heterozygotes vs. wild-type; b = homozygote variant vs. wild-type, p = p-value.